Initial Results Of Hyalex Freestyle Knee Implant First-In-Human Clinical Studies To Be Presented At The ISAKOS Congress 2025

(MENAFN- PR Newswire)

LEXINGTON, Mass., May 29, 2025 /PRNewswire/ -- Hyalex Orthopaedics, a privately held medical device company developing joint preservation technologies based on the transformative HYALEX HYDROSURFTM materials platform, today announced that initial results of the company's first-in-human clinical studies of its Freestyle Knee Implant will be highlighted in a presentation at the International Society of Arthroscopy, Knee Surgery, and Orthopaedic Sports Medicine (ISAKOS) Congress 2025. Presented data will include findings from a Poland-based first-in-human trial and a U.S.-based Early Feasibility Study (EFS). The ISAKOS Congress 2025 is taking place June 8-11, 2025, in Munich, Germany.

Details of the HYALEX FreestyleTM Knee Implant presentation are as follows:

Title: First-in-Human Study of Biomimetic Synthetic Cartilage Implant to Treat Painful Knee Cartilage Lesions

Presenting Author: Marcin E. Domzalski, M.D., professor at Veteran's Memorial Hospital of Medical University of Lodz in Konstantynów Lódzki, lódzkie, Poland.

Session: Scientific Papers

Date/Time: Tuesday, June 10, 2025, 2:55 – 3:00 p.m. Central European Summer Time

The HYALEX Freestyle Knee Implant is designed to enable patients suffering from cartilage damage and early osteoarthritis of the femoral condyle(s) to regain an active lifestyle by replicating the function and structure of natural cartilage. Professor Domzalski will present preliminary findings from the company's first-in-human studies of the HYALEX Freestyle Knee Implant, which represents the first clinical applications of the transformative implant technology.

Hyalex recently announced that it intends to expand its U.S.-based EFS, as well as its ex-U.S. first-in-human study, to a global pivotal study. This trial expansion was allowed based on the U.S. Food and Drug Administration's approval of Hyalex's supplemental Investigational Device Exemption (IDE) application for the HYALEX Freestyle Knee Implant, supporting the company's continued efforts to bring this next-generation orthopedic solution to patients in need.

To learn more about the HYALEX Freestyle Knee EFS, please visit .

About Hyalex Orthopaedics

Hyalex is a privately held medical device company headquartered in Lexington, MA, developing transformational joint preservation technologies for diseased and damaged joints. The HYALEX HYDROSURFTM materials platform is protected by more than 17 patents and trademarks worldwide. The HYALEX Freestyle Knee system has received Investigational Device Exemption (IDE) approval from the United States Food and Drug Administration for a clinical trial in the United States.

For more information:

Contact Information:

Tim Brons
Vida Strategic Partners (media)
646-319-8981
[email protected]

SOURCE Hyalex Orthopaedics

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE? 440k+
Newsrooms &
Influencers 9k+
Digital Media
Outlets 270k+
Journalists
Opted In GET STARTED

MENAFN29052025003732001241ID1109610359